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Abstract
Background: Human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. The HPV
vaccine has a very significant impact on the incidence of cervical cancer. The present study aimed to investigate
the impact of prophylactic quadrivalent HPV vaccine in the treatment of women with cervical intraepithelial
neoplasia (CIN 1–3).
Methods: This randomized controlled trial was conducted in the Shahid Sadoughi University of Medical Sciences
(SSUMS), Yazd, Iran, from October 2011 to November 2015 in women with histologically confirmed residual/
recurrent CIN 1 or high-grade CIN (CIN 2–3). Eligible women were assigned randomly to an intervention and a
control group. Women in the intervention group were given HPV vaccinations while those in the control group
were not. Participants were followed up for 24 months. Primary and secondary outcomes, and adverse effects of
the treatment in the two groups were compared using Student’s t test, the chi-square test, or Fisher’s exact test. P
values < 0.05 or less were considered statistically significant.
Results: Three-hundred and twelve women were randomized to the two groups; the data of 138 in the
intervention group and 104 in the control group were analyzed. The mean age of the women was 32.59 ± 4.85
years. Differences in age, marital status, and grades of CIN weren’t significant between the two groups. At the end
of the two-year follow-up period, the number of women with CIN 2–3 in the intervention and control groups was
reduced by 75% (from 93 to 23) versus 40% (from 69 to 41). The efficacy of the HPV vaccine in women with CIN 1–
3 was 58.7% (p = 0.018). No serious adverse effects related to the vaccines were reported.
Conclusions: The prophylactic quadrivalent HPV vaccine after treatment may have a therapeutic effect in women
with residual/recurrent CIN 1 or high-grade CIN (CIN 2–3).
Trial registration: Iranian Registry of Clinical Trials, IRCT20190603043801N1. Registered 24 July 2019 –
Retrospectively registered, http://www.irct.ir/user/trial/40017/view
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Background
Cervical cancer is one of the most common cancers in
women throughout the world [1–3]. More than 500,000
new cases occur every year and cervical cancer accounts
for more than 250,000 deaths per year [1, 2]. In Iran, the
mean age-standardized mortality rates (ASMR) for cervical
cancer were reported as 1.04 per 100,000 [3]. The human
papillomavirus (HPV) transmitted by sexual contact was
found to be one of the risk factors for cervical, breast [4, 5],
anal, and oropharyngeal cancer [6, 7]. Permanent high-risk
HPV infections are considered as a major cause of intrae-
pithelial neoplasia (CIN 1–3) [6, 8, 9], and the first stage in
the progression of cervical cancer [10, 11]. Such that the
prevalence of HPV infection in cervical cancer patients was
more highly than healthy Iranian women (76% vs.7%) [3].
The immune system frequently eradicates CIN, but in some
cases, cervical cancer emerges from CIN [12]. CIN is classi-
fied as mild (CIN 1), moderate (CIN 2), or severe (CIN 3)
dysplasia [13, 14].
Conservative treatment, including the loop electrosurgical
excision procedure (LEEP) and cold-knife conization, can
effectively eradicate CIN 2–3 [15, 16]. However, the recur-
rence of CIN after conservative treatment has been re-
ported between 5 and 30% [16]. Once the lesions are
detected, the patients must be followed up and treated
again as required [17–19].
Recent studies support the therapeutic role of the
HPV vaccine [16, 20, 21]. It has been seen that pre-
surgery HPV vaccination in women with HPV-related
diseases significantly reduces the incidence of CIN 2–3
[16, 22]. But the efficacy of the HPV vaccination in pre-
venting subsequent disease after conservative treatment
of CIN 2–3 has not been investigated so far [16] .
A population of more than 25 million Iranian women
older than 15 years of age are at risk of cervical cancer
due to a lack of knowledge about HPV infection [23]
and changing trends in sexual behavior [3, 24, 25]. Fur-
thermore, HPV vaccines have not yet been introduced in
Iran. On the other hand, the HPV vaccine is costly and
its availability limited in the country, while affluent
countries, HPV vaccinations are given to all women aged
9 to 26 years [26]. The efficacy of the HPV vaccination
in preventing subsequent diseases after conservative
treatment in women with CIN1–3 who missed the
vaccination before developing the disease has not been
investigated. So, this study was designed to assess the
impact of prophylactic quadrivalent HPV vaccine in the
treatment of women with cervical intraepithelial neopla-
sia (CIN 1–3).
Methods
Study design and patients
A randomized controlled trial was conducted in
gynecological clinics affiliated to the Shahid Sadoughi
University of Medical Sciences (SSUMS), Yazd, Iran,
from October 2011 to November 2015 to evaluate the
effect of HPV vaccine post-surgery in the treatment of
women with CIN 1 or high-grade CIN (CIN 2–3). The
study sample size was calculated at least 138 women in
each group based on the study by the Future II Study
Group (Vila), considering p1 = proportion of CIN cured
by vaccine = 0.183, p2 = proportion of CIN cured by pla-
cebo 5.6 [27], an alpha error of 0.05 and study power of
80%. In this study, 20% of the sample was assumed as
lost to follow up so, the sample size was considered at
150 women in each group. According to the calculated
sample size, women who had the following inclusion cri-
teria were enrolled in the study by a convenient sam-
pling method. The inclusion criteria for both groups
included women: 1) a) age 21–45 years, b) currently not
pregnant, c) no abnormal results on a previous cervical
smear test, d) no more than four sexual partners in the
course of their lives, e) women with histologically con-
firmed residual/recurrent CIN 1 or high-grade CIN
(CIN 2–3), and f) treated by conservative treatment.
Three-hundred and twenty-eight women were assessed
for eligibility. Those who did not fulfil the inclusion cri-
teria or declined to participate were excluded (Fig. 1).
Blinding and intervention
All patients were included in the study after they re-
ceived sufficient explanation about the study objectives
and signed the written informed consent. Three-
hundred and twelve women were randomized to the
intervention group or the control group through a
computer-generated random table of quadruple block
numbers (block size of four). One nurse who was not
involved in the research prepared the coded envelopes
allocated the women into two groups. The main investi-
gator and the gynecologist who assessed the outcomes
were blinded to the group allocation. The statistician
who analyzed the outcomes was also unaware of the al-
locations. Women in the intervention group received
conservative treatment according to the ASCCP algo-
rithm [28], along with quadrivalent HPV vaccinations
(Gardasil). Gardasil (Merck and Co., Inc., Whitehouse
Station, NJ, USA) targets HPV types 6, 11, 16, and 18.
The vaccine was given as a series of intramuscular injec-
tions of 0.5 mL on day 1, month 2, and month 6 [29].
Forty-eight to 72 h after the injection, the patients were
checked for skin complications, fever, headache, pain,
and inflammation. Women in the control group received
treatment according to the ASCCP algorithm [28], with-
out the HPV vaccination.
Outcomes, measurements, and follow-up
Throughout the 2 years, the patients were managed in
accordance with the protocol published earlier [28]. The
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efficacy of the HPV vaccine in the treatment of CIN 1–3
was defined as a primary outcome. To measure this criter-
ion, the women underwent a gynecological examination, a
Pap test, and colposcopy and biopsy on day 1 and at
months 7, 12, 18, and 24. At each visit, at least two biopsy
specimens were taken at the colposcopy to evaluate the re-
sponse to treatment despite the normal appearance of the
cervix. Biopsy specimens were obtained from various areas
using separate instruments. All Pap testing and histologic
evaluations were performed in the same laboratory. Pap
tests were read using the Bethesda system [30, 31]. The
results of visual inspection of the cervix and histological
biopsy were recorded on the checklist and each patient’s
medical records. A normal cytology and a negative colpos-
copy were not interpreted as the absence of disease, but a
negative histological result of the biopsy was considered to
indicate no disease.
Women who became pregnant, received just one dose
of the vaccine, had severe allergies to HPV vaccines or
were unwilling to cooperate (missing cytology results)
were excluded from this study (Fig. 1).
The efficacy of the vaccine is expressed as a propor-
tionate reduction in the disease attack rate (AR). The
difference in AR between unvaccinated (ARU) and vacci-
nated (ARV) persons can be calculated from the relative
risk (RR) of disease in the vaccinated group, using the
following formula: VE ¼ ARU−ARVARU  100 [32].
As secondary outcomes, we compared the efficacy of
two and three doses of the HPV vaccine to treat CIN 1–
3 and adverse effects of the HPV vaccine, such as head-
ache, pain, swelling, redness, and skin rash.
Statistical analysis
All the statistical analysis was performed using the Stat-
istical Package of Social Sciences (SPSS), version 16.0
(SPSS Inc., Chicago, IL., USA). Kolmogorov-Smirnov
was used to assess the normality of data distribution.
The results for the quantitative variables were reported
in mean ± SD format and the ordinal qualitative vari-
ables were reported in frequency and percentages. All
descriptive data had a normal distribution. Therefore,
Fig. 1 Flowchart of the study
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the student’s t-test was used to compare quantitative
parametric variables between the two groups. To com-
pare characteristics of the categorical variables between
the two groups, the chi-square test or Fisher’s exact test
were used. P values < 0.05 or less were considered statis-
tically significant.
Results
In all 328 women were assessed for eligibility and 312
patients were included in the study. One hundred fifty-
eight women were assigned to the intervention group
and 154 to the control group. Twenty and 50 women in
the intervention and control groups, respectively, were
lost during the follow-up period due to pregnancy, lack
of cooperation, and allergies to the vaccine. Ultimately,
the analysis was done with the data of 138 women in the
intervention group and 104 cases in the control group
(Fig. 1). The mean age of the women was 32.59 ± 4.85
years. Based on the result, differences in age, marital
status, and grades of CIN were statistically significant
between the two groups (Table 1). Demographic and
clinical characteristics of the two groups are shown in
Table 1.
At the two-year follow-up, 75.6% of CIN 1 lesions, 78%
of CIN 2 lesions, and 72.1% of CIN 3 lesions in women in
the intervention group had regressed. The total number of
patients with CIN 1, 2, 3, who returned to normal differed
significantly in the two groups (p = 0.02, 0.03, 0.03). The
development of CIN in the two groups after 2 years of
follow-up is summarized in Table 2.
As shown in Table 2, the overall efficacy of the vaccine
(two or more vaccinations) in women with CIN 1, 2, 3
was 54.9, 63.3, and 52.5% respectively. The efficacy of
two and three doses of HPV vaccine in treating CIN 1
was 38.6 and 63.1%, and their efficacy in treating CIN 2
was 50 and 72.2%, respectively. The difference between
the efficacy of different doses of the vaccine for the
treatment of residual/recurrent CIN 1 and CIN 2 was
statistically significant (p = 0.012, p = 0.042).
All women with CIN 3 received three doses of the vac-
cination. The efficacy of the vaccine in women who re-
ceived three doses was superior to its efficacy in women
who received two doses; both of these groups were su-
perior to controls. Data concerning the efficacy of the
vaccine in regard to CIN 1–3 are shown in Table 2.
Of 35 patients who received two doses of the vaccine,
only one woman (2/9%) experienced a headache. Of 103
patients who were given three doses of the vaccine, 10
(9.7%) reported headache. The difference was not signifi-
cant on the chi-square test (p = 0.191). Women who re-
ceived two doses of the vaccine reported redness and rash
at the injection site in 34 cases (n = 35; 97.1%), whereas
women who received three doses reported redness and
rash in 93 cases (n = 103; 90.3%). The difference was not
significant (p = 0.191) on the chi-square test. No further
complications were registered in the study.
Discussion
To be able to prevent cervical cancer in women aged
less than 45 years the quadrivalent HPV vaccine was de-
veloped [33]. Recently, the therapeutic role of the HPV
vaccine has been claimed in some studies [16, 20, 21]. In
the present study, the impact of prophylactic quadriva-
lent HPV vaccine in the treatment of women with
cervical intraepithelial neoplasia (CIN 1–3) was investi-
gated. Based on the result, a 58.7% reduction in the
recurrence of CIN 1–3 was reported in women who
received two or more doses of the quadrivalent HPV
vaccination after the conservative treatment of CIN 1–3.
Satisfactory results of therapeutic HPV vaccinations have
been also reported in women with CIN 1–3 in previous
clinical trials [20, 21].
At the two-year follow-up, 45.7 and 75.6% of CIN 1
lesions regressed in control and intervention groups
Table 1 Demographic and clinical characteristics of the two groups
Variable Control group (N = 104) HPV vaccine group (N = 138) P value
Age, (y)
Min- Max 22–41 22–42
Mean ± SD 33.04 ± 4.6 31.7 ± 4.8 0.5*
Marital status; N (%)
Married 103 (99) 136 (98.5)
Divorced 1 (1) 2 (1.45) 0.8**
CIN 1; N (%) 35 (33.7) 45 (32.6)
CIN 2; N (%) 35 (33.7) 50 (36.2) 0.3***
CIN 3; N (%) 34 (32.6) 43 (31.2)
Two-dose vaccination; N (%) – 35 (26.4) –
Three-dose vaccination; N (%) – 103 (74.6)
Abbreviations: Y year; N number; CIN Cervical intraepithelial neoplasia; SD Standard deviation, *Student’s t test, ** Fisher’s exact test, ***Chi-squared test
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respectively. Since CIN 1 does not pose a significant risk
factor for developing CIN 3, then it is not considered for
screening, or treatment [34]. Accordingly, in this study,
we just included women with residual/recurrent CIN 1.
The overall efficacy of two further doses of the HPV vac-
cine in the treatment of residual/recurrent CIN 1 was
54.9%. In accordance with these data, the efficacy of the
vaccine in the prevention of recurrent CIN 1 lesions has
been reported in studies 42.6% [35] and 48.3% [22].
In the present study, at the two-year follow-up, the
vaccine reduced the number of women with CIN 2–3 by
75% (93 to 23 women). The overall efficacy of two fur-
ther doses of the HPV vaccine in the treatment of CIN 2
and CIN 3 was 63.3 and 52.5% respectively. In line with
our data, in Joura and co-workers’ study, the efficacy of
the vaccination in the reduction of high-grade cervical
disease was 64.9% (95% CI 20.1 to 86.3%) [22]. In
addition, a prospective nonrandomized study conducted
in Korea showed that the post-surgical HPV vaccination
has been accompanied by a lower risk of recurrence of
CIN 2. So that the recurrence of CIN 2 lesions in HPV
vaccinated and non-vaccinated groups was 2.5% (9/360)
vs. 7.2% (27/377), (p < 0.01) [16].
In the present study, at the two-year follow-up, 22% of
CIN 2 lesions in women in intervention group persisted
or progressed to CIN 3, and 27.9% of CIN 3 lesions per-
sisted. In Tainio and coworkers’ study 3160 women with
CIN 2 lesions were investigated in terms of spontaneous
regression, persistence, or progression to CIN 3 or can-
cer. At the end of the follow-up period, 18% of CIN 2 le-
sions had progressed, 32% persisted, and 50% had
regressed [36].
Since the single dose of the HPV vaccine has not been
proven to be effective [37–40], therefore, in the present
study women who received just one dose of the vaccine
were excluded. The efficacy of two and three doses of
the HPV vaccine in the treatment of residual/recurrent
CIN 1 was 38.6 and 63.1%, respectively. The efficacy of
two and three doses for the treatment of CIN 2 was 50,
and 72.2%, respectively. Although the results of some
studies suggest that three doses of HPV vaccination is
highly more effective than two doses in preventing of
occurrence of cervical neoplasia [38], but some studies
reported no significant difference between two and three
doses [40, 41]. In our study, we noted a big difference in
efficacy with three doses of HPV vaccine versus two
doses of vaccine. In line with our results, in Basu and
coworkers’ study, the efficacy of three and two doses of
the vaccine against high-grade lesions in recipients was
46% versus 21% [38]. Since the primary purpose of the
present study was not to compare the efficacy of two or
three doses of the HPV vaccine, so randomization was
not performed on this basis. Therefore, this issue calls
for another ethically well-formed longer studies with
appropriate design.
In the present study, one woman in the control group
actually developed invasive cervical cancer. While, in
McCredie and co-workers’ study, invasive cervical cancer
occurred in almost 30% of women with untreated CIN 3
developed over a 30-year follow-up period. Women with
untreated CIN 3 were at high risk of cervical cancer,
while the risk was very low in women who were receiv-
ing conservative treatment throughout [42]. The differ-
ence observed in our study with McCredie et al. study is
that, in our study, all women (intervention or control
group) received lesions-related treatment, including
LEEP, cold-knife conization, ablation according to proto-
cols [28]. Therefore, the effect of vaccination after the
treatment of CIN 1–3 was assessed in women who
missed the chance to be vaccinated before developing
the disease. In fact, the vaccination is being used to force
the immune system to produce antibodies that can block
spontaneous HPV infection and reduces the recurrence
of the CIN lesions [11, 16, 20, 22]. The results of studies
show that immunizing against HPV infection is able to
protect patients from precancerous cervical conditions
and is very likely to reduce cervical cancer rates in the
future [16, 20, 22]. Since the prevention of all types of
Table 2 Efficacy of the HPV vaccine in women with CIN after 2 years of follow-up
Variable Post-injection condition of the lesion after 2 years of follow-up Efficacy (%) *P value
Normal CIN 1 CIN 2–3
N (%)
CIN 1 Control (N = 35) 16 (45.7) 19 (54.3) – 54.9 0.02
Two more doses of vaccination (N = 45) 34 (75.6) 11 (24.4) –
CIN 2 Controls (N = 35) 14 (40) – 21 (60) 63.3 0.01
Two more doses of vaccination (N = 50) 39 (78) – 11 (22)
CIN 3 **Controls (N = 34) 14 (41.2) – 20 (58.2) 52.5 0.03
***Two more doses of vaccination (N = 43) 31 (72.1) – 12 (27.9)
Abbreviations: N Number; CIN Cervical intraepithelial neoplasia
* Data were analyzed with Fisher’s exact test
**One woman in the control group actually developed invasive cervical cancer
***All women with CIN 3 received 3 doses of the vaccination
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cervical cancer is not possible with the HPV vaccine, so
women still need to go for regular screening even after
they have been vaccinated [43].
The side effects of the HPV vaccine in the present
study were headaches, redness, and rash at the injection
site. The most frequent side effect of the prophylactic
quadrivalent HPV vaccine in Goncalves et al. was pain
and swelling at the injection site. Other complications
included fatigue, headache, fever, and gastrointestinal
symptoms in a later stage [44]. Safety outcomes were
similar in the various investigated groups [45, 46]. In a
follow-up study conducted by Romanowski et al., a ser-
ious adverse event was reported by 30 (8%) women in
the vaccine group versus 37 (10%) in the placebo group.
None was considered to be related or possibly related to
the vaccination, and no deaths occurred [45].
Although the present study yielded important data, the
limitations are worthy of mention. Due to the high costs
of the vaccine, our results are based on the evaluation of
a small number of persons. The second limitation was
the short duration of follow-up. The third limitation was
that we disregarded the women’s HPV status (positive or
negative. Finally, the women’s age range and the dosage
of the vaccine were not regarded as important factors in
the design of the study and their randomization to the
control and intervention groups. Studies have shown
that the rate of regression of lesions differs in various
age groups [47]. Such that the regression rate more
highly was reported among women below 30 years of
age than (60% vs.11%) [36]. The fact that all women with
CIN 3 received three doses of the vaccine might have
influenced the results of the present study. Therefore,
long-term studies of an appropriate design will be
needed to investigate the long-term efficacy of the
HPV vaccine in preventing the progression of cervical
lesions.
Conclusions
The present study showed that a prophylactic quadriva-
lent HPV vaccine actually can be used for therapeutic pur-
poses in women with histologically confirmed residual/
recurrent CIN 1 or high-grade cervical intraepithelial neo-
plasia (CIN 2–3). All women (vaccinated and non-
vaccinated) with cervical lesions were followed up for 2
years. The study demonstrated the efficacy of the vaccine
in the treatment and resolution of cervical lesions. In fact,
nearly a reduction of nearly 60% was noted in the recur-
rence cervical lesions (CIN 1–3) after two further doses of
the vaccine. Our data concur with those of other studies
which showed that the efficacy of the vaccine was higher
in women who received three doses of the vaccine than in
those who received two doses, for both high-grade and
low-grade lesions [39, 48].
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